Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development.

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Alvotech SA

Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market.

Teva Pharmaceuticals and Alvotech expand biosimilars partnership

On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions of several medicines and is conducting phase 2 trials for TEV-48574, an experimental drug for moderate to severe ulcerative colitis or Crohn's disease. Despite an agreement with Nevada, Teva's share price has dropped over 15% since the start of 2023, underperforming competitors like Dr. Reddy's Laboratories and Viatris.

Teva Pharmaceutical's Remarkable Growth In 2023: A Success Story

Analysts at UBS have upgraded their rating on Teva Pharmaceuticals, a manufacturer of generic pharmaceuticals, to ‘Neutral' from ‘Sell' citing a now balanced risk/reward profile. They also raised their price target from US$7 to US$8.

Teva Pharmaceuticals upgraded with improving product mix set to bolster gross margins

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available o.

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. today announces further positive data from the pan-European PEARL study investigating the impact of AJOVY® (fremanezumab) on the prevention of migraine in a real-world setting,1 due to be completed in 2024. The data from the 3rd interim analysis2 reveals that almost 60% of patients achieved a ≥50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acu.

Teva's 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

DISH Network

Equitrans Midstream

Plug Power

Peloton

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Well-Known Buy-Rated Stocks Under $10 Could Explode Higher in July

Bristol-Myers

Pfizer

Bristol Myers Squibb stock is too cheap to ignore. Pfizer has more good news on the way than meets the eye.

3 Bargain Stocks to Buy on the Dip

TEVA's new plan will see it shift its focus and resources to innovative medicines like Austedo that enjoy higher margins than generics. Austedo has been performing well historically, with plans to grow its sales to $2.5 billion in 2027 from the $1.2 billion expected in 2023. If the new growth plan is successful, the upside will be immense as TEVA is currently valued like a failing company.

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that six abstracts revealing benefits of AJOVY (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2023 American Headache Society (AHS) Annual Scientific Meeting, held June 15-18 in Austin, Texas. Featured data will include an oral presentation of the Phase 4 UNITE randomized clinical study, invest.

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Kentucky to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $1.407 million, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made. This is the sixth settlement of price-fixing cla.

Teva Reaches Agreement With Kentucky to Settle the State's Price Fixing Claims

Cantaloupe, Inc

Asbury Automotive Group

David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, disclosed his equity portfolio for the first quarter of 2023 last month.

David Abrams Adds to Cantaloupe Stake, Trims 2 Top Holdings

Allergan

CVS Health

Walgreens

Teva, Allergan, CVS and Walgreens said enough states agreed to final agreements, adding to the billions flowing to communities.

Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It

AbbVie

New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.

NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan

Teva Pharmaceutical Industries (NASDAQ:TEVA) has agreed to pay the state of Nevada $193 million to settle claims that its marketing efforts helped fuel opioid addiction, the state announced Wednesday.  Nevada was one of just two states not part of the $4.35 billion national settlement with the Israel-based company in 2022.

Teva Pharmaceutical settles $193M opioid suit with the state of Nevada

Teva Pharmaceuticals TEVA, +2.07% announced Thursday that it has resolved its nationwide settlement agreement related to opioid claims brought by states and reached a separate settlement with the state of Nevada. The company will pay Nevada $193 million over 20 years, resolving the case ahead of a trial that was set to start in August.

Teva concludes nationwide opioid settlement agreement, reaches separate settlement with Nevada

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Company has fully resolved its nationwide settlement agreement related to opioid claims brought by U.S. states, their subdivisions, and special districts, and has reached a separate settlement with the final state of Nevada. Teva will pay Nevada $193 million over 20 years (including all fees and costs), and this settl.

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Pharmaceutical Industries on Wednesday agreed to pay Nevada $193 million to settle claims that its marketing practices fueled opioid addiction, the state announced.

Teva to pay Nevada $193 million over role in opioid epidemic

SAN FRANCISCO--(BUSINESS WIRE)--Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva's Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma manag.

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Teva is refocusing its efforts on biosimilar medicines and cost-cutting. It's also looking to broaden its pipeline more generally to develop more generics.

Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023. Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD. Data presented will include interim findings from the START trial, a Phase 4 s.

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

JetBlue Airways

Under Armour

5 Very Well Known Buy-Rated Stocks Under $10 Could Explode Higher This Summer

Amphastar Pharma

Dr. Reddy's Labs

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

3 Generic Drug Stocks to Watch Amid Macro Headwinds

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association's (APA) 2023 Annual Meeting taking place on May 20-24, 2023. Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for th.

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual Meeting

The new corporate strategy aims to deliver a “pivot to growth," the drugmaker said.

News for Teva Pharmaceutical Stock (TEVA)